Does cyclin E immunoexpression in gastric cancer correlate with clinicopathological parameters?
We have not demonstrated any significant relationship between cyclin E immunopositivity and any of the usual clinicopathological parameters (especially lymph node involvement) and therefore cyclin E immunohistochemistry alone does not appear to have a role in the assessment of gastric cancer currently.
We demonstrate the potential of modulating APP steady-state expression level as a safe and effective approach for reducing Aβ deposition in AD transgenic model mice.